Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

Small molecule inhibition of ERK dimerization prevents tumorigenesis by Ras-ERK pathway oncogenes


ABSTRACT: About 50% of human malignancies exhibit unregulated signalling through the Ras-ERK1/2 (ERK) pathway, as a consequence of activating mutations in members of Ras and Raf families. However, the quest for alternative Ras-ERK pathway-directed therapies is desirable. Upon phosphorylation ERK dimerize. We had previously demonstrated that dimerization is essential for ERK extranuclear but not nuclear signaling. Furthermore, by molecular biology approaches, we showed that specifically inhibiting ERK extranuclear component, by impeding ERK dimerization, is sufficient for curtailing tumor progression. Here, we have identified a small molecule inhibitor for ERK dimerization in vitro and in vivo that, without affecting ERK phosphorylation, prevents tumorigenesis driven by Ras-ERK pathway oncogenes, both in cellular and animal models. Importantly, this compound is unaffected by resistance-acquisition processes that hamper “classical” Ras-ERK pathway inhibitors. Thus, ERK dimerization inhibitors provide the proof of principle for two novel concepts in cancer therapy: 1) The blockade of sublocalization-specific sub-signals, rather than total signals, as a means of effectively counteracting oncogenic Ras-ERK signaling. 2) Targeting regulatory protein-protein interactions such as dimerization, rather than catalytic activities, within a signaling route, as an approach for producing effective anti-tumoral agents. Strategies aimed at preventing aberrant flux through this route remain an attractive option for therapeutic intervention in cancer. In this respect, drugs inhibiting the kinase activities of BRaf and MEK have yielded promising results. A375p cells treated with10 μM of either DEL22379, SCH772984 or DMSO as a control for two hours. mRNA from A375p cells was extrated using RNeasy mini kit (Qiagen, Germany) according to the manufacturer's instructions. Cells were previously treated with10 μM of either DEL22379, SCH772984 or DMSO as a control for two hours.

ORGANISM(S): Homo sapiens

SUBMITTER: Piero Crespo 

PROVIDER: E-GEOD-68230 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

Similar Datasets

2015-04-24 | GSE68230 | GEO
| PRJNA788144 | ENA
| PRJNA282079 | ENA
2019-05-14 | E-GEOD-68230 | ExpressionAtlas
2020-02-03 | E-MTAB-8111 | biostudies-arrayexpress
2024-10-04 | GSE273721 | GEO
2024-06-10 | PXD032257 | Pride
2023-03-11 | PXD035758 | Pride
2023-03-11 | PXD035817 | Pride
2020-02-03 | E-MTAB-8110 | biostudies-arrayexpress